Aileron Therapeutics is a clinical stage chemoprotection oncology company. Co.'s product candidate, ALRN-6924, is a MDM2/MDMX dual inhibitor that utilizes its proprietary peptide drug technology. When used as a chemoprotective agent, ALRN-6924 is designed to activate p53, which in turn upregulates p21, an inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. The ALRN stock yearly return is shown above.
The yearly return on the ALRN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALRN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|